Clinical trial
Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures
NCT00161629 · Wyeth is now a wholly owned subsidiary of Pfizer, Industry · Completed
Key facts
| NCT number | NCT00161629 |
|---|---|
| Title | Study Evaluating rhBMP-2/CPM in Closed Distal Radius Fractures |
| Official title | A Phase 1 Dose-Escalating, Double-Blind, Placebo-Controlled, Multicenter, Safety and Feasibility Study of Recombinant Human Bone Morphogenetic Protein-2 (rhBMP-2)/Calcium Phosphate Matrix (CPM) as an Adjuvant Therapy for Closed Distal Radius Fractures |
| Lead sponsor | Wyeth is now a wholly owned subsidiary of Pfizer, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Radius Fractures |
| Intervention type | Drug |
| Interventions | rhBMP-2/CPM |
| Enrollment | 40 |
| Start date | Sep 1, 2005 |
| Completion | Jan 1, 2007 |
| First posted | Sep 12, 2005 |
| Last update posted | Dec 5, 2007 |
| Countries | Finland, France |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: